Wednesday, January 20, 2021

Very Brief Blog: LUCIRA Files for $115M IPO; has EUA for Home-Test Version for PCR COVID

 Update; Press on Feb 4 suggests the IPO is $150M.  Here.


The COVID pandemic has seen enormous new investments in R&D, including for point of care tests.  For example, I saw an advertisement for the NIH RADx-funded PCR device from VISBY a few weeks ago (here).

Here's a new one, where we have both some news reports and a full-length IPO document for LUCIRA, intended as a home-use POCT that uses LAMP amplification for very rapid COVID results.

Genomeweb - here - writes,

In November, the company received Emergency Use Authorization from the US Food and Drug Administration for the Lucira COVID-19 All-in-One Test Kit, a rapid, at-home, real-time loop-mediated isothermal amplification (LAMP) SARS-CoV-2 test available by prescription that runs on a handheld batter-powered device. An over-the-counter version of the test is expected to be submitted to the FDA later this year. 

See an IPO press release here.  But of particular interest and detail, see the 287-page IPO filing here.



On the same theme of POCT COVID: see a (subscription) deep dive article at Genomeweb by Kelsy Ketchum on January 21, on the startup STARTUP DETECT, formerly HOMODEUS.  Here.


Update: A few days after LUCIRA, the molecular microbiology firm TALIS also filed for an IPO - here.